INDmoney
Lupin Share Price
₹2292.20
+42.00
(+1.87%)
as on
🔔 Product Launch Alert
Lupin receives US FDA approval for Brivaracetam Oral Solution, initiating launch in the US market, estimated annual sales of $135 million.
Lupin Stock Performance
as on February 25, 2026 at 9:31 pm IST
Day's Low
Day's High
₹2,254.80₹2,299.70
1.63%
Downside
0.33%
Upside
52 Week's Low
52 Week's High
₹1,795.20₹2,299.7021.68%
Downside
0.33%
Upside
Lupin share price movements today
- Previous Close
- ₹2,250.20
- Open
- ₹2,267.20
- Volume
- 11.04L
- Upper Circuit
- ₹2,475.20
- Lower Circuit
- ₹2,025.20
- Day's Low - High
- ₹2,254.80 - ₹2,299.70
- 52 Week Low - High
- ₹1,795.20 - ₹2,299.70
Lupin Historical Returns
- 1 Month Return
- + 4.64 %
- 3 Month Return
- + 10.18 %
- 1 Year Return
- + 18.48 %
- 3 Year Return
- + 243.75 %
- 5 Year Return
- + 119.62 %
Lupin Fundamentals
as on February 25, 2026 at 4:01 pm IST
Market Cap
₹1,02,843.87 Cr
Return on Equity (ROE)
17.7
PE Ratio (TTM)
22.12
Return on capital employed (ROCE)
21.32
Industry PE ratio
41.66
Beta (LTM)
0.86
P/B Ratio
3.81
Dividend Yield
0.59
PEG Ratio
0.57
Quarterly Earnings Growth YOY
37.45
EPS (TTM)
72.41
Sector
Pharmaceuticals
Book Value
376.77
Technical Analysis
Bullish
View Technical Analysis
Lupin Stock Valuation
as on February 25, 2026 at 4:01 pm IST
Lupin in the last 5 years
Lowest (-6437.86x)
December 3, 2018
Today (22.12x)
February 24, 2026
Industry (41.66x)
February 24, 2026
Highest (517.33x)
December 2, 2022
Today’s Price to Earnings Ratio: 22.12x
Lupin Ltd vs Peer Comparison
Compare market cap, revenue, PE, and other key metrics of Lupin with its industry peers.
Company | Analyst View | Market Cap(in ₹ Cr) | 5 Year CAGR | Debt to Asset Ratio | Net Profit(in ₹ Cr) | Yearly Revenue(in ₹ Cr) |
|---|---|---|---|---|---|---|
| BUY | 1,02,843.87 | 23.92% | 0.63 | 3,306 | 22,707 | |
| BUY | 9,397.85 | -9.98% | 0.52 | 413 | 2,013 | |
| BUY | 67,628.54 | 6.98% | 0.60 | 3,483 | 31,723 | |
| HOLD | 90,948.46 | 21.27% | 0.61 | 4,614 | 23,241 | |
| BUY | 56,025.63 | 16.74% | 0.00 | 1,414 | 6,445 |
Market expectation of Lupin Stock
Common consensus of the market based on various publicly available news, publications,brokerage expectation and market data
62.86%
Buy
28.57%
Hold
8.57%
Sell
Lupin Stock’s Investor Sentiment and Interest
Investment in Lupin Ltd Shares on INDmoney has grown by 42.62% over the past 30 days, indicating increased transactional activity.
Time period: to
Change:42.62% versus previous 30 day period
Search interest for Lupin Ltd Stock has increased by 58% in the last 30 days, reflecting an upward trend in search activity.
Time period: to
Change:58% versus previous 30 day period
Lupin Ltd Quarterly Profit & Loss
Figures in Rupees Crores
Lupin Ltd Annual Profit & Loss
Figures in Rupees Crores
Lupin Ltd Cash Flow
Figures in Rupees Crores
Lupin Stock Shareholding Pattern
Numbers in percentages
Mutual Funds that own Lupin Stock
Check out the Mutual Funds with significant holdings in Lupin.
Funds | Holdings | Shares Held | |
|---|---|---|---|
 HDFC Balanced Advantage Fund Direct Plan Growth Option | 1.15% | 5686457 | |
HDFC Large Cap Fund -Direct Plan - Growth Option | 2.51% | 4615980 | |
 Mirae Asset Large & Midcap Fund Direct Plan Growth | 2.23% | 4388151 | |
HDFC Flexi Cap Fund -Direct Plan - Growth Option | 0.93% | 4200000 | |
 Nippon India Pharma Fund - Direct Plan - Growth Plan | 7.88% | 2883991 |
Lupin Corporate Actions
View detailed summary of the earnings and dividend history of Lupin.
Lupin Ltd Earnings Results
Lupin Ltd’s net profit jumped 37.47% since last year same period to ₹1,175.55Cr in the Q3 2025-2026. On a quarterly growth basis, Lupin Ltd has generated -20.46% fall in its net profits since last 3-months.
Read More about Earnings ResultsLupin Ltd Dividends May,2025
In the quarter ending March 2025, Lupin Ltd has declared dividend of ₹12.00 per share on 14 May 2025 - translating a dividend yield of 0.53%.
Read More about Dividends
Indices Featuring Lupin Stock
Check stock indices that include Lupin.
Insights on Lupin Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTFII Holding Up
Foreign Institutions have increased holdings from 20.49% to 21.49% in Dec 2025 quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 4 quarters, 5.72K Cr → 7.28K Cr (in ₹), with an average increase of 7.6% per quarter
- POSITIVE IMPACT
Price Rise
In the last 7 days, LUPIN stock has moved up by 1.1%
- POSITIVE IMPACT
Best in 3 Years
In the last 3 years, LUPIN has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
NO EFFECTAgainst Peers
In the last 1 year, Torrent Pharmaceuticals Ltd has given 45.1% return, outperforming this stock by 26.6%
NEGATIVE IMPACTPromoter Holding Down
Promoters have decreased holdings from 46.90% to 46.89% in Dec 2025 quarter
- NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 2 quarters, 1.47K Cr → 1.17K Cr (in ₹), with an average decrease of 20.5% per quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 6.06% to 6.03% in Dec 2025 quarter
- NEGATIVE IMPACT
MF Holding Down
Mutual Funds have decreased holdings from 20.57% to 18.01% in Dec 2025 quarter
Lupin Stock Futures & Options Contracts
View the latest movement in Lupin Futures & Options, including strike prices, expiry dates, and percentage changes.
Lupin Options
Lupin Futures
About Lupin Ltd
The company's top products include a wide range of prescription and over-the-counter drugs, including antibiotics, cardiovascular medications, antidiabetics, and anti-asthmatics. Lupin Ltd also manufactures and markets a variety of branded products, including Metoject, Lupitac, and Lupizole. In addition, the company produces a number of popular generic drugs, such as Amlodipine, Montelukast, and Cetirizine.
Lupin Ltd is one of the world's leading manufacturers of APIs, with a portfolio that includes more than 200 APIs and intermediates. The company also produces a range of animal health products, such as veterinary vaccines, feed supplements, and pet care products.
Revenue: ₹7,100.45Cr as on December 2025 (Q3 FY26)
Net Profit: ₹1,180.51Cr as on December 2025 (Q3 FY26)
Listing date: 30 Nov, 1994
Chairperson Name: M D Gupta
| Organisation | Lupin Ltd |
| Industry | Pharmaceuticals |
| CEO | M D Gupta |
| E-voting on shares | Click here to vote |
FAQs
What is Lupin share price today?
Lupin share price today stands at ₹2292.2 as on at the close of the market. Lupin share today touched a day high of ₹2299.7 and a low of ₹2254.8.
What is the 52 week high and 52 week low range for Lupin share?
Lupin touched a 52 week high of ₹2299.7 and a 52 week low of ₹1795.2. Lupin share price today i.e. is closed at ₹2292.2, which is -0.33% down from its 52 week high and 27.68% up from its 52 week low.
What is Lupin's market capitalisation today?
Lupin market capitalisation is ₹1,02,843.87 Cr as on .
How to buy Lupin shares?
To buy Lupin shares, you need to follow these steps:
- Open a Demat account and Trading account on INDmoney
- Fund your Trading account
- Search for LUPIN or Lupin Ltd on the INDmoney app to check live prices of the stock
- Click on Buy or SIP to place an order to invest in Lupin shares. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.
What is Lupin trading volume today?
Lupin trading volume is 11.04L as on . This means that 11.04L shares of Lupin were bought and sold on the stock market during today's trading session.